Swiss Medtech Warns of Declining Attractiveness Amid Cost Pressures

The Swiss medtech sector, which employs around 72,000 people and contributes 10 percent to Switzerland’s industrial value-added, has seen average annual revenue growth of 5.5 percent in 2024 and 2025—nearly double the 6.4 percent average over the past decade. Yet concerns persist over eroding competitiveness, with over half of surveyed firms rating their location’s attractiveness worse than five years ago. Investment plans have stalled, with 43 percent of companies reporting no new capital expenditures—a decline from the highest point in survey history. Meanwhile, the emphasis on traditional Swiss expertise as a draw for foreign investment has waned, replaced by a focus on access to cutting-edge technology.